What is the level of liabilities of Altimmune this year?
Altimmune has a debt balance of 15.8 M USD this year.
Altimmune Liabilities 2025
Altimmune Liabilities
15.8 M USD
Ticker
ALT
ISIN
US02155H2004
WKN
A2N5Z6
In 2025, Altimmune's total liabilities amounted to 15.8 M USD, a -4.49% difference from the 16.54 M USD total liabilities in the previous year.
Altimmune Aktienanalyse
What does Altimmune do?
Altimmune Inc is a biopharmaceutical company specializing in the development of immunotherapies. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland, USA. Altimmune ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Altimmune's Liabilities
Altimmune's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Altimmune's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Altimmune's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Altimmune's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Altimmune’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Altimmune stock
What were the liabilities of Altimmune compared to the previous year?
The liabilities of Altimmune have increased by -4.49% dropped compared to the previous year.
What are the consequences of high debt for investors of Altimmune?
High liabilities can pose a risk for investors of Altimmune, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Altimmune?
Low liabilities mean that Altimmune has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Altimmune affect the company?
An increase in liabilities of Altimmune can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Altimmune affect the company?
A decrease in the liabilities of Altimmune can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Altimmune?
Some factors that can influence the liabilities of Altimmune include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Altimmune so important for investors?
The liabilities of Altimmune are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Altimmune take to modify the liabilities?
To change its liabilities, Altimmune can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Altimmune pay?
Over the past 12 months, Altimmune paid a dividend of 873 USD . This corresponds to a dividend yield of about 23,780.99 %. For the coming 12 months, Altimmune is expected to pay a dividend of 0 USD.
What is the dividend yield of Altimmune?
The current dividend yield of Altimmune is 23,780.99 %.
When does Altimmune pay dividends?
Altimmune pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Altimmune?
Altimmune paid dividends every year for the past 0 years.
What is the dividend of Altimmune?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Altimmune located?
Altimmune is assigned to the 'Health' sector.
Wann musste ich die Aktien von Altimmune kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Altimmune from 2/3/2017 amounting to 2.91 USD, you needed to have the stock in your portfolio before the ex-date on 2/6/2017.
When did Altimmune pay the last dividend?
The last dividend was paid out on 2/3/2017.
What was the dividend of Altimmune in the year 2024?
In the year 2024, Altimmune distributed 0 USD as dividends.
In which currency does Altimmune pay out the dividend?
The dividends of Altimmune are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Altimmune
Our stock analysis for Altimmune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Altimmune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
